Healthcare’s Once-in-a-Generation Disruption

The cost of healthcare in the United States continues to rise and the availability continues to decline. Healthcare spending accounts for 18% of U.S. GDP, and the costs in the U.S. are the highest in the world, increasing 130% in just the last decade. With this complexity comes an opportunity for entrepreneurs, innovators, and investors. iSelect is focused on finding technologies and innovations that reduce costs, increase accessibility, and improve quality of care.

iSelect Portfolio Companies

iSelect focuses on early-stage healthcare companies that are poised to help push the next healthcare revolution forward. We deliberately invest in companies that can make a positive impact on our society, as well as on the bottom line.

Meet Our Selection Committee

Our Healthcare Selection Committee consists of industry and subject matter experts who help guide iSelect’s investment decisions. With firsthand experience and a true pulse on the industry, we consider these individuals key to our success in finding and investing in healthcare innovation.

Ruchir Sehra, M.D., is a medtech executive with extensive experience in early (private), mid (public), and late stage (acquisition) medical device companies in various health and disease areas. Dr. Sehra currently serves as the CEO…

Read full bio >

Surekha Trivedi is VP Strategic Development at Danaher. She is a Senior Strategy, M&A, and Product Development Executive with a deep understanding of the life sciences, diagnostics, and healthcare markets. Recognized as a strategy expert…

Read full bio >

Jill Davies is Co-Founder and Chief Executive Officer for GeneMatters. Jill has more than 20 years’ experience in the genetics field, with leadership in clinical services, telehealth, product development, business development and operations. Prior to…

Read full bio >

Vice President of Research at Matatu, Nathan McNulty is microbiologist with a passion for addressing complex problems in healthcare, nutrition, and agriculture using innovative technologies, carefully conducted science, and teamwork.

Read full bio >

Emily Fassi is a board-certified genetic counselor with experience counseling adults and children about genetic diagnoses and predisposition to genetic conditions. She currently works at the Mountain States Tumor Institute with patients who have a…

Read full bio >

Dr. David Messina has spent the last 20 years in computational biology and genetics. He worked on the Human Genome Project at Washington University in Saint Louis, mapped disease genes at the University of Chicago,…

Read full bio >

Dr. Bruce German is a Professor and Chemist of Food Science and Technology at the University of California, Davis and researches the role of fats and other components in the diet. He develops ways to…

Read full bio >

A regulatory professional with over 27 years of experience in the medical products industry, Melissa currently serves as Founder, President and CTO at Graematter, Inc. and Senior VP Regulatory at Topera. Specialties include regulatory intelligence research and reporting,…

Read full bio >

Andrew Daniels

Andy Daniels is a seasoned business executive and successful entrepreneur, an active angel investor, and serves on multiple governing boards with companies in the areas of venture capital, wealth management, agriculture, healthcare, technology innovation, commodity…

Read full bio >

Dr. Paul D. Olivo, M.D., Ph.D., has been the Chief Scientific Officer of Apath, LLC since 2000 and served as its President. Dr. Olivo is an Entrepreneur-in-Residence at BioGenerator, where he previously served as a…

Read full bio >

Bobby Sandage

Bobby Sandage is currently President and CEO of Euclises, Chairman of the Board of Immunophotonics, member of the board of directors of EDIS, and a member of the Cultivation Capital life sciences fund investment committee. He was…

Read full bio >

Gian Cavallini oversees the development and execution of Advanced ICU Care’s medical staffing growth strategy and leads the implementation of various initiatives to position the company for continued growth. His expertise in development and operations,…

Read full bio >

Michael Beat

Presently leading Arch Cancer Care as Medical Director, Dr. Beat is a local expert in collaborative prostate cancer management. At a national level, he contributes to physician leadership committees within the US Oncology Network. Having earned an executive…

Read full bio >

Mr. Beuttenmuller possesses over 30 years experience in Corporate Finance with Emerson Electric, Esse Health, Essence Healthcare and Innovare. He is experienced in financial analysis, risk management, mergers and acquisitions, new business development, start-ups, strategic…

Read full bio >

Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation at UUniversity of Iowa Roy J. and Lucille A. Carver College of Medicine and former Professor of Medicine and Genetics at Washington University…

Read full bio >

Dr. John Talley, Chief Science Officer for Euclises Pharmaceuticals and SARmont,  brings over thirty years experience and a record as one of the world’s most successful medicinal chemists. He is best known as the co-inventor…

Read full bio >

Bryce Rutter

Dr. Rutter is founder and CEO of Metaphase Design Group, a design firm serving industrial, commercial and consumer product and packaging clients internationally.  He is an acknowledged specialist in ergonomic product design and a leading…

Read full bio >

Mark has served as ProteoSense’s CEO since 2013. Previously, Mark served as CEO/COO of several startups, including Assurex Health (2006-09). Mark earned a B.S. in Electrical Engineering from the Univ. of Dayton and an M.S….

Read full bio >

Before joining OTMIR in 2016, Brian Buntaine worked for more than 15 years in the life sciences industry. He began his career as a lab manager at Washington University in St. Louis. In 2003, Brian joined…

Read full bio >

Edwards was employed for 42 years in the pharmaceutical and life sciences arenas. From 1990 to 2010, he held Regulatory Affairs positions of increasing responsibility at TAP/Takeda Global Research & Development Center, Lake Forest, Illinois. …

Read full bio >

Michael Nichols

Michael Nichols, Ph.D. presently serves as an investor and C level management for various startups. He serves as an Analyst for Vinlogx, a platform that acquires, stores, and analyses internal vehicle information enabling solutions across…

Read full bio >

David Christenson

David Christenson joined BioGenerator as an Entrepreneur-in-Residence in 2015 focusing primarily on healthcare and specifically in information technology, care delivery and payment, and services. Over a 30-year career, David has developed a substantive background in…

Read full bio >

Renaldo Cataldo

An accomplished senior executive with start-ups, growth, and turn-around organizations, Renato developed a healthcare technology corporation, HealthTech Solutions, from a small start-up of 3 people to a national provider of technical solutions to health care…

Read full bio >

Join Our Healthcare Innovation Network

Join the thousands of entrepreneurs, investors, and industry professionals driving the future of healthcare.

Resources and News

RNA Is Becoming the New DNA, Opening New Doors in Medicine

RNA Is Becoming the New DNA, Opening New Doors in Medicine

If a person’s DNA is the roadmap of their lifetime health, their RNA is more of a real-time barometer, recording what happens in their body on a minute-by-minute basis. Our DNA stores and transfers genetic information, but remains little changed throughout our lives. At best, it can tell us about the probability we will someday develop various diseases — whether or not we will get cancer, for instance, or be susceptible to diabetes or heart disease — but it  can’t tell us much about our current health.

read more
Gila Therapeutics Completes Phase I Clinical Trial

Gila Therapeutics Completes Phase I Clinical Trial

Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help...

read more
Resistant Hypertension: Ending the Death Sentence

Resistant Hypertension: Ending the Death Sentence

Physicians have been fascinated with blood and the circulatory system for hundreds of years. Records dating back to early Roman times prove that bloodletting was in wide use as a treatment for disease at least 2,000 years ago, and leeches have been used in medicine...

read more
Gila Therapeutics: New Solutions for the Obesity Crisis

Gila Therapeutics: New Solutions for the Obesity Crisis

Obesity is the single largest health crisis facing the world today. More than one billion people worldwide are overweight or obese, accounting for 38% of the population. In the U.S., a full 68% of adults, or some 200 million people, are overweight. On average, obese...

read more